Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Care United Research

Neither a doctor nor a teaching hospital

Research payments

$608,147

163 payments

Through program year 2025, Care United Research is reported as receiving $608,147 in research payments, across 163 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $240,917 120
2024 Research $351,052 41
2023 Research $16,178 2

Breakdown

Who paid Research payments · program years 2023–2025
  1. Braintree Laboratories, Inc. $277,065 36 payments
  2. Boehringer Ingelheim International GmbH $228,758 114 payments
  3. Eli Lilly and Company $38,849 8 payments
  4. Biogen, Inc. $36,015 1 payment
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $20,783 3 payments
  6. Boehringer Ingelheim Pharma GmbH & Co.KG $6,677 1 payment
Studies the money was for Research payments · program years 2023–2025
  1. A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis $277,065 36 payments
  2. A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis $204,677 99 payments
  3. A Phase 2 Study of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (CYPRESS) (CYPRESS) $36,015 1 payment
  4. A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. $28,179 12 payments
  5. -Ph III MASH pivotal trials $23,361 7 payments
  6. A Study of Daily Oral Orforglipron (Ly3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity Or Overweight at Increased Cardiovascular Risk (Achieve-4) $20,360 4 payments
  7. A Study of Daily Oral Orforglipron (Ly3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity Or Overweight at Increased Cardiovascular Risk (Achieve-4) $16,178 2 payments
  8. A Master Protocol for A Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes $2,311 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record